| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/MED.21388 |
| P698 | PubMed publication ID | 27297498 |
| P50 | author | Margaret Brimble | Q15848279 |
| Zaid Amso | Q61122455 | ||
| Jillian Cornish | Q50315176 | ||
| P2860 | cites work | Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor | Q22004174 |
| Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum | Q22010686 | ||
| Ghrelin is a growth-hormone-releasing acylated peptide from stomach | Q22010951 | ||
| MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia | Q24290092 | ||
| Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a | Q24300324 | ||
| Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization | Q24310115 | ||
| Human alpha 2-macroglobulin is an osteogenic growth peptide-binding protein | Q24313039 | ||
| Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients | Q24631987 | ||
| Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro | Q24675778 | ||
| Leaky ribosomal scanning in mammalian genomes: significance of histone H4 alternative translation in vivo | Q24798502 | ||
| The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion | Q28138378 | ||
| Characterization of apelin, the ligand for the APJ receptor | Q28141574 | ||
| Galanin receptor subtypes | Q28145418 | ||
| The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in orthopaedic applications | Q28262713 | ||
| Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery | Q28273375 | ||
| The future of peptide-based drugs | Q28281702 | ||
| Apelin and its receptor are expressed in human osteoblasts | Q28303722 | ||
| Hepcidin deficiency undermines bone load-bearing capacity through inducing iron overload | Q28507401 | ||
| The receptor attributable to C-type natriuretic peptide-induced differentiation of osteoblasts is switched from type B- to type C-natriuretic peptide receptor with aging | Q28571552 | ||
| Substance P stimulates late-stage rat osteoblastic bone formation through neurokinin-1 receptors | Q28577956 | ||
| Dwarfism and early death in mice lacking C-type natriuretic peptide | Q28588954 | ||
| Substance P stimulates bone marrow stromal cell osteogenic activity, osteoclast differentiation, and resorption activity in vitro | Q37251736 | ||
| Anti-resorptive therapies for osteoporosis. | Q37257184 | ||
| Increased osteoblast functions in the presence of BMP-7 short peptides for nanostructured biomaterial applications | Q37320869 | ||
| Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation | Q37339719 | ||
| Teriparatide: a review of its use in osteoporosis. | Q37354140 | ||
| Priming integrin alpha5 promotes human mesenchymal stromal cell osteoblast differentiation and osteogenesis. | Q37413484 | ||
| Targeting the ghrelin receptor to regulate food intake | Q37442033 | ||
| Osteogenic differentiation of human mesenchymal stem cells on α5 integrin binding peptide hydrogels is dependent on substrate elasticity | Q37649448 | ||
| Osteoporosis: impact on health and economics | Q37686083 | ||
| IGF-IEc expression, regulation and biological function in different tissues | Q37759904 | ||
| Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal | Q37874775 | ||
| Parathyroid hormone analogues in the treatment of osteoporosis | Q37900475 | ||
| New understanding and treatments for osteoporosis | Q37969683 | ||
| The role of ghrelin in the control of energy balance | Q37976357 | ||
| Iron homeostasis in osteoporosis and its clinical implications | Q38004771 | ||
| Mechanisms in endocrinology: Ghrelin: the differences between acyl- and des-acyl ghrelin | Q38035140 | ||
| Targeting integrins to promote bone formation and repair | Q38077443 | ||
| Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis | Q38232951 | ||
| Ghrelin is an Osteoblast Mitogen and Increases Osteoclastic Bone Resorption In Vitro | Q38345504 | ||
| Endothelin-1 promotes osteoprogenitor proliferation and differentiation in fetal rat calvarial cell cultures | Q38349359 | ||
| Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis | Q38459806 | ||
| Functional expression of N-formyl peptide receptors in human bone marrow-derived mesenchymal stem cells | Q38464455 | ||
| Short-term and long-term effects of osteoporosis therapies. | Q38473594 | ||
| Functional and transcriptomic analysis of the regulation of osteoblasts by mechano-growth factor E peptide | Q38485815 | ||
| Improving the osteogenic efficacy of BMP2 with mechano growth factor by regulating the signaling events in BMP pathway | Q38890787 | ||
| Wnt/β-catenin signaling mediates osteoblast differentiation triggered by peptide-induced α5β1 integrin priming in mesenchymal skeletal cells | Q38915530 | ||
| Selective osteogenesis by a synthetic mineral inducing peptide for the treatment of osteoporosis | Q38957931 | ||
| Pituitary adenylate cyclase-activating polypeptide (PACAP) signalling enhances osteogenesis in UMR-106 cell line. | Q38967086 | ||
| Effects of mouse hepcidin 1 treatment on osteoclast differentiation and intracellular iron concentration | Q38972072 | ||
| The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling | Q39212192 | ||
| Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib | Q39330638 | ||
| New cyclic peptides with osteoblastic proliferative activity from Dianthus superbus | Q39398084 | ||
| Mechano-growth factor E peptide inhibits the differentiation and mineralization of osteoblasts | Q39425012 | ||
| An isolated cryptic peptide influences osteogenesis and bone remodeling in an adult mammalian model of digit amputation | Q39440583 | ||
| Hepcidin increases intracellular Ca2+ of osteoblast hFOB1.19 through L-type Ca2+ channels | Q39475421 | ||
| Ghrelin directly regulates bone formation. | Q51504751 | ||
| First-in-human testing of a wirelessly controlled drug delivery microchip. | Q51541952 | ||
| Effect of varied release kinetics of the osteogenic thrombin peptide TP508 from biodegradable, polymeric scaffolds on bone formation in vivo. | Q51550160 | ||
| Repair of rabbit segmental defects with the thrombin peptide, TP508. | Q51633187 | ||
| The evaluation of ectopic bone formation induced by delivery systems for bone morphogenetic protein-9 or its derived peptide. | Q51765433 | ||
| Presence of galanin-like immunoreactivity in mesenchymal and neural crest origin tissues during embryonic development in the mouse. | Q51784331 | ||
| Skeletal analysis of the long bone abnormality (lbab/lbab) mouse, a novel chondrodysplastic C-type natriuretic peptide mutant. | Q51822129 | ||
| Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation. | Q52178500 | ||
| Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch. | Q52200362 | ||
| Gene expression of bone matrix proteins and endothelin receptors in endothelin-1-deficient mice revealed by in situ hybridization. | Q52529454 | ||
| The effect of bone morphogenetic protein-2, bone morphogenetic protein-7, parathyroid hormone, and platelet-derived growth factor on the proliferation and osteogenic differentiation of mesenchymal stem cells derived from osteoporotic bone. | Q52847181 | ||
| The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. . | Q53328360 | ||
| The use of immobilized osteogenic growth peptide on gradient substrates synthesized via click chemistry to enhance MC3T3-E1 osteoblast proliferation. | Q53358642 | ||
| Biomimetic surface modification using synthetic oligopeptides for enhanced guided bone regeneration in beagles. | Q53426429 | ||
| The identification of a heparin binding domain peptide from bone morphogenetic protein-4 and its role on osteogenesis. | Q53464974 | ||
| Increased Bone Turnover and Possible Accelerated Fracture Healing in a Murine Model With an Increased Circulating C-Type Natriuretic Peptide. | Q53550819 | ||
| rhBMP-2, rhVEGF(165), rhPTN and thrombin-related peptide, TP508 induce chemotaxis of human osteoblasts and microvascular endothelial cells. | Q53622168 | ||
| Bone formation is enhanced by thrombin-related peptide TP508 during distraction osteogenesis. | Q53629243 | ||
| Bone formation on two-dimensional poly(DL-lactide-co-glycolide) (PLGA) films and three-dimensional PLGA tissue engineering scaffolds in vitro. | Q54023207 | ||
| Peptide-based activation of alpha5 integrin for promoting osteogenesis. | Q54311172 | ||
| Synthetic osteogenic growth peptide promotes differentiation of human bone marrow mesenchymal stem cells to osteoblasts via RhoA/ROCK pathway. | Q54575678 | ||
| Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. | Q55058660 | ||
| Central and peripheral expression of galanin in response to inflammation | Q57990477 | ||
| Molecular Basis of Ligand Recognition by Integrin α5β1 | Q58057976 | ||
| Annexin 1 peptides protect against experimental myocardial ischemia-reperfusion: analysis of their mechanism of action. | Q43771278 | ||
| Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice | Q43974287 | ||
| Dentonin, a fragment of MEPE, enhanced dental pulp stem cell proliferation | Q44137977 | ||
| How to blast osteoblasts? Novel dicarba analogues of amylin-(1-8) to treat osteoporosis | Q44243006 | ||
| Expression and Splicing of the Insulin‐Like Growth Factor Gene in Rodent Muscle is Associated with Muscle Satellite (stem) Cell Activation following Local Tissue Damage | Q44401232 | ||
| Bone induction by biomimetic PLGA-(PEG-ASP)n copolymer loaded with a novel synthetic BMP-2-related peptide in vitro and in vivo | Q44546612 | ||
| Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism | Q44605245 | ||
| Amylin fasting plasma levels are decreased in patients with osteoporosis | Q44647489 | ||
| Effects and differentiation activity of IGF-I, IGF-II, insulin and preptin on human primary bone cells. | Q44650839 | ||
| A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo | Q44812046 | ||
| Ala-scan of ghrelin (1-14): interaction with the recombinant human ghrelin receptor | Q44941270 | ||
| A fragment of the hypophosphatemic factor, MEPE, requires inducible cyclooxygenase-2 to exert potent anabolic effects on normal human marrow osteoblast precursors | Q45078877 | ||
| Connective tissue growth factor is a downstream mediator for preptin-induced proliferation and differentiation in human osteoblasts | Q45158996 | ||
| Ghrelin regulates proliferation and differentiation of osteoblastic cells. | Q45218899 | ||
| Characterization of new stable ghrelin analogs with prolonged orexigenic potency | Q45249630 | ||
| Preparation and ectopic osteogenesis in vivo of scaffold based on mineralized recombinant human-like collagen loaded with synthetic BMP-2-derived peptide | Q45771355 | ||
| Lentiviral-mediated integrin α5 expression in human adult mesenchymal stromal cells promotes bone repair in mouse cranial and long-bone defects | Q45873674 | ||
| Organization and expression analysis of the zebrafish hepcidin gene, an antimicrobial peptide gene conserved among vertebrates. | Q45956866 | ||
| Postmenopausal women with osteoporosis may be associated with high endothelin-1. | Q45969308 | ||
| Murine preosteoblast differentiation induced by a peptide derived from bone morphogenetic proteins-9. | Q46039342 | ||
| Enhanced cell attachment to anorganic bone mineral in the presence of a synthetic peptide related to collagen | Q46125345 | ||
| Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis | Q46139256 | ||
| Assembly of collagen-binding peptide with collagen as a bioactive scaffold for osteogenesis in vitro and in vivo | Q46279649 | ||
| Early gene and protein expression associated with osteoblast differentiation in response to fish collagen peptides powder | Q46288506 | ||
| Neuro-hormonal control of bone metabolism: vasoactive intestinal peptide stimulates alkaline phosphatase activity and mRNA expression in mouse calvarial osteoblasts as well as calcium accumulation mineralized bone nodules | Q46290538 | ||
| Correlation between induction of expression of biglycan and mineralization by C-type natriuretic peptide in osteoblastic cells. | Q46291320 | ||
| Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice | Q46294704 | ||
| Enhanced cell attachment and osteoblastic activity by P-15 peptide-coated matrix in hydrogels | Q46497508 | ||
| Osteogenesis induced by a bone forming peptide from the prodomain region of BMP-7. | Q46505734 | ||
| Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function | Q46528690 | ||
| Stimulation of intramembranous bone repair in rats by ghrelin. | Q46533401 | ||
| Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions | Q46659830 | ||
| The potential impact of new National Osteoporosis Foundation guidance on treatment patterns | Q46676022 | ||
| Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma | Q46712881 | ||
| Immobilization of a bone and cartilage stimulating peptide to a synthetic bone graft | Q46887966 | ||
| Osteogenic growth peptide modulates fracture callus structural and mechanical properties | Q47318273 | ||
| Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose | Q47325378 | ||
| Osteogenic growth peptide incorporated into PLGA scaffolds accelerates healing of segmental long bone defects in rabbits | Q47418503 | ||
| MAP kinase signaling cascades and gene expression in osteoblasts | Q47774538 | ||
| Differential effects of natriuretic peptide stimulation on tissue-engineered cartilage | Q47853606 | ||
| Multi-center clinical evaluation of combination anorganic bovine-derived hydroxyapatite matrix (ABM)/cell binding peptide (P-15) as a bone replacement graft material in human periodontal osseous defects. 6-month results | Q47861122 | ||
| Potential impact of sitagliptin on collagen-derived dipeptides in diabetic osteoporosis. | Q47909401 | ||
| Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects | Q48114511 | ||
| Detection of C-type natriuretic peptide (CNP) transcript in the rat heart and immune organs | Q48311650 | ||
| C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. | Q49017266 | ||
| Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues. | Q50473451 | ||
| Effects of egg yolk-derived peptide on osteogenic gene expression and MAPK activation. | Q50638721 | ||
| ASARM-truncated MEPE and AC-100 enhance osteogenesis by promoting osteoprogenitor adhesion. | Q50797268 | ||
| Local injection of thrombin-related peptide (TP508) in PPF/PLGA microparticles-enhanced bone formation during distraction osteogenesis. | Q50878490 | ||
| Innervation of periosteum and bone by sympathetic vasoactive intestinal peptide-containing nerve fibers. | Q50909472 | ||
| Neuropeptides stimulate human osteoblast activity and promote gap junctional intercellular communication. | Q50946373 | ||
| Experimental research on ectopic osteogenesis of BMP2-derived peptide P24 combined with PLGA copolymers. | Q51006336 | ||
| Injectable gel with synthetic collagen-binding peptide for enhanced osteogenesis in vitro and in vivo. | Q51028637 | ||
| Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. | Q51168965 | ||
| A study of biologically active peptide sequences (P-15) on the surface of an ABM scaffold (PepGen P-15) using AFM and FTIR. | Q51401122 | ||
| Single and combined use of human parathyroid hormone (PTH) (1-34) on areal bone mineral density (aBMD) in postmenopausal women with osteoporosis: evidence based on 9 RCTs | Q34742975 | ||
| Amylin and adrenomedullin: novel regulators of bone growth. | Q34779817 | ||
| Expression and regulatory role of receptors for vasoactive intestinal peptide in bone cells | Q34804000 | ||
| Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications | Q34805764 | ||
| Chronic central administration of Ghrelin increases bone mass through a mechanism independent of appetite regulation. | Q34812037 | ||
| N-formyl-methionyl-leucyl-phenylalanine (fMLP) promotes osteoblast differentiation via the N-formyl peptide receptor 1-mediated signaling pathway in human mesenchymal stem cells from bone marrow | Q34948033 | ||
| Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma | Q34997270 | ||
| Significance of C-type natriuretic peptide (CNP) in endochondral ossification: analysis of CNP knockout mice | Q34998675 | ||
| Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. | Q35006651 | ||
| The association between the serum C-peptide level and bone mineral density | Q35072996 | ||
| Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis | Q35092617 | ||
| Bone morphogenetic proteins, their antagonists, and the skeleton | Q35109618 | ||
| Genetic determination of the cellular basis of the ghrelin-dependent bone remodeling | Q35113493 | ||
| Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits | Q35197522 | ||
| The anabolic effects of parathyroid hormone therapy | Q35198551 | ||
| Recruitment of progenitor cells by an extracellular matrix cryptic peptide in a mouse model of digit amputation | Q35230870 | ||
| Neuropeptide Y, substance P, and human bone morphogenetic protein 2 stimulate human osteoblast osteogenic activity by enhancing gap junction intercellular communication. | Q35567595 | ||
| Association between low C-peptide and low lumbar bone mineral density in postmenopausal women without diabetes | Q35597894 | ||
| Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives | Q35744492 | ||
| The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway | Q35860566 | ||
| Molecular and cellular mechanisms of the anabolic effect of intermittent PTH | Q36016775 | ||
| Early Effects of Single and Low-Frequency Repeated Administration of Teriparatide, hPTH(1-34), on Bone Formation and Resorption in Ovariectomized Rats | Q36042959 | ||
| The ABCs of BMPs | Q36050270 | ||
| Effects of P-15 Peptide Coated Hydroxyapatite on Tibial Defect Repair In Vivo in Normal and Osteoporotic Rats | Q36174144 | ||
| Mechanical signals, IGF-I gene splicing, and muscle adaptation | Q36197814 | ||
| Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. | Q36233759 | ||
| Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions | Q36314468 | ||
| P-15 small peptide bone graft substitute in the treatment of non-unions and delayed union. A pilot clinical trial | Q36495738 | ||
| Osteoporosis: now and the future | Q36564425 | ||
| Thrombin peptide TP508 stimulates cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues | Q36641786 | ||
| Sixteen weeks of hexarelin therapy in aged dogs: effects on the somatotropic axis, muscle morphology, and bone metabolism | Q36831972 | ||
| A single injection of the anabolic bone agent, parathyroid hormone-collagen binding domain (PTH-CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice. | Q36957141 | ||
| The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo | Q37034189 | ||
| Expression of galanin and a galanin receptor in several sensory systems and bone anlage of rat embryos | Q37056101 | ||
| Increased bone mass in mice lacking the adipokine apelin | Q37087683 | ||
| Safety of parathyroid hormone for the treatment of osteoporosis | Q37145404 | ||
| Growth hormone, insulin-like growth factors, and the skeleton | Q37147591 | ||
| The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. | Q37166798 | ||
| Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling | Q37176560 | ||
| A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study | Q37213526 | ||
| Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias | Q37244601 | ||
| Developmental regulation of the growth plate | Q29618969 | ||
| Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis | Q29619487 | ||
| How cells read TGF-beta signals | Q29619993 | ||
| A novel potent vasoconstrictor peptide produced by vascular endothelial cells | Q29620540 | ||
| Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation | Q30441987 | ||
| Parathyroid hormone receptor directly interacts with dishevelled to regulate beta-Catenin signaling and osteoclastogenesis | Q30494322 | ||
| Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis | Q30868288 | ||
| The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats | Q30873578 | ||
| Human Galanin: Molecular Cloning Reveals a Unique Structure | Q33265553 | ||
| Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy | Q33412690 | ||
| Substance P activates the Wnt signal transduction pathway and enhances the differentiation of mouse preosteoblastic MC3T3-E1 cells | Q33580629 | ||
| Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women | Q33586747 | ||
| Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa | Q33665366 | ||
| Orexin regulates bone remodeling via a dominant positive central action and a subordinate negative peripheral action | Q33717450 | ||
| Antiosteoporotic effect of orally administered yolk-derived peptides on bone mass in women | Q33723041 | ||
| Update in new anabolic therapies for osteoporosis | Q33786824 | ||
| HDAC4 integrates PTH and sympathetic signaling in osteoblasts | Q33797044 | ||
| Endothelin and post-ganglionic sympathetic neurons | Q33811422 | ||
| Neuropeptide substance P improves osteoblastic and angiogenic differentiation capacity of bone marrow stem cells in vitro | Q33876274 | ||
| Casein kinase 2 beta-subunit is a regulator of bone morphogenetic protein 2 signaling | Q34032756 | ||
| Phospholipase C signaling via the parathyroid hormone (PTH)/PTH-related peptide receptor is essential for normal bone responses to PTH. | Q34132577 | ||
| Surface immobilization of MEPE peptide onto HA/β-TCP ceramic particles enhances bone regeneration and remodeling. | Q34249760 | ||
| Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia | Q34314761 | ||
| The nuclear localization of MGF receptor in osteoblasts under mechanical stimulation | Q34323600 | ||
| Metabolism of growth hormone releasing peptides | Q34458391 | ||
| Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome | Q34501396 | ||
| Lower circulating preptin levels in male patients with osteoporosis are correlated with bone mineral density and bone formation | Q34567531 | ||
| The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness | Q34575514 | ||
| Regulation of bone mass by Wnt signaling | Q34576629 | ||
| Proteasome inhibitors in the treatment of multiple myeloma | Q34611676 | ||
| In vitro cytocompatibility evaluation of MGF-Ct24E chemically grafted and physically blended with maleic anhydride modified poly(D, L-lactic acid). | Q34675232 | ||
| Parathyroid hormone for the treatment of osteoporosis: a systematic review | Q34695988 | ||
| TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility | Q34713446 | ||
| Teriparatide or alendronate in glucocorticoid-induced osteoporosis | Q34713779 | ||
| Casein kinase 2 regulates in vivo bone formation through its interaction with bone morphogenetic protein receptor type Ia. | Q39505619 | ||
| Protective effect of egg yolk peptide on bone metabolism | Q39627712 | ||
| C-type natriuretic peptide: Structural studies, fragment synthesis, and preliminary biological evaluation in human osteosarcoma cell lines. | Q39728491 | ||
| Amylin(1-8) is devoid of anabolic activity in bone | Q39744641 | ||
| Early osteogenic differentiation of mouse preosteoblasts induced by collagen-derived DGEA-peptide on nanofibrous phage tissue matrices. | Q39779818 | ||
| cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells | Q39842814 | ||
| A novel collagen-binding peptide promotes osteogenic differentiation via Ca2+/calmodulin-dependent protein kinase II/ERK/AP-1 signaling pathway in human bone marrow-derived mesenchymal stem cells | Q40016731 | ||
| Apelin stimulates proliferation and suppresses apoptosis of mouse osteoblastic cell line MC3T3-E1 via JNK and PI3-K/Akt signaling pathways. | Q40207646 | ||
| Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis | Q40360482 | ||
| Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells | Q40404949 | ||
| Accelerated bone repair with the use of a synthetic BMP-2-derived peptide and bone-marrow stromal cells. | Q40492043 | ||
| Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system" | Q40512524 | ||
| Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway. | Q40528212 | ||
| Prolonged ectopic calcification induced by BMP-2-derived synthetic peptide. | Q40549773 | ||
| Structure-activity studies of orexin a and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands | Q40588357 | ||
| MEPE has the properties of an osteoblastic phosphatonin and minhibin. | Q40590136 | ||
| Attachment, proliferation, and migration of marrow stromal osteoblasts cultured on biomimetic hydrogels modified with an osteopontin-derived peptide. | Q40618012 | ||
| E3 Ubiquitin Ligase Smurf1 Mediates Core-binding Factor α1/Runx2 Degradation and Plays A Specific Role in Osteoblast Differentiation | Q40649010 | ||
| Bioactive pseudopeptidic analogues and cyclostereoisomers of osteogenic growth peptide C-terminal pentapeptide, OGP(10-14). | Q40740588 | ||
| Mitogenic G(i) protein-MAP kinase signaling cascade in MC3T3-E1 osteogenic cells: activation by C-terminal pentapeptide of osteogenic growth peptide [OGP(10-14)] and attenuation of activation by cAMP. | Q40809278 | ||
| Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats | Q40809292 | ||
| Ipamorelin, the first selective growth hormone secretagogue | Q40832148 | ||
| Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. | Q40840986 | ||
| Stimulation by retinoids of the natriuretic peptide system of osteoblastic MC3T3-E1 cells. | Q41155146 | ||
| Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate | Q41304383 | ||
| Design of biomimetic habitats for tissue engineering with P-15, a synthetic peptide analogue of collagen | Q41646614 | ||
| The action of GH/IGF-I/IGFBP in osteoblasts and osteoclasts | Q41684793 | ||
| Efficacy, effectiveness and side effects of medications used to prevent fractures. | Q41704607 | ||
| Biological designer self-assembling peptide nanofiber scaffolds significantly enhance osteoblast proliferation, differentiation and 3-D migration | Q41971530 | ||
| The effect of collagen I mimetic peptides on mesenchymal stem cell adhesion and differentiation, and on bone formation at hydroxyapatite surfaces | Q42151053 | ||
| Tailored integrin-extracellular matrix interactions to direct human mesenchymal stem cell differentiation | Q42287329 | ||
| Expression of galanin and galanin receptor-1 in normal bone and during fracture repair in the rat | Q42452930 | ||
| Growth hormone stimulates proliferation and differentiation of normal human osteoblast-like cells in vitro | Q42483109 | ||
| Inhibitory effect of amylin on basal and parathyroid hormone-stimulated bone resorption in cultured neonatal mouse calvaria | Q42505874 | ||
| Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus | Q42510908 | ||
| Enhanced osteogenesis by collagen-binding peptide from bone sialoprotein in vitro and in vivo | Q42511847 | ||
| Protective effect of apelin on cultured rat bone marrow mesenchymal stem cells against apoptosis | Q42557243 | ||
| Thrombin related peptide TP508 promoted fracture repair in a mouse high energy fracture model | Q42610559 | ||
| The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts | Q42611864 | ||
| Mitogenic action of osteogenic growth peptide (OGP): role of amino and carboxy-terminal regions and charge | Q42614776 | ||
| Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label ph | Q42665480 | ||
| Ghrelin inhibits the apoptosis of MC3T3-E1 cells through ERK and AKT signaling pathway | Q42710000 | ||
| ETA receptor mediates the signaling of endothelin-1 in osteoblast-like cells | Q42798109 | ||
| Stimulation by C-type natriuretic peptide of the differentiation of clonal osteoblastic MC3T3-E1 cells | Q42814044 | ||
| Egg yolk soluble protein stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells | Q42828567 | ||
| Osteogenic growth peptide C-terminal pentapeptide [OGP(10-14)] acts on rat bone marrow mesenchymal stem cells to promote differentiation to osteoblasts and to inhibit differentiation to adipocytes | Q42830500 | ||
| Differentiation of preosteoblasts using a delivery system with BMPs and bioactive glass microspheres | Q42830598 | ||
| Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism | Q42830752 | ||
| Osteopromotion with synthetic oligopeptide-coated bovine bone mineral in vivo | Q42832404 | ||
| Collagen-derived dipeptide prolyl-hydroxyproline promotes differentiation of MC3T3-E1 osteoblastic cells | Q42834732 | ||
| C-type natriuretic peptide regulates endochondral bone growth through p38 MAP kinase-dependent and -independent pathways | Q42861749 | ||
| Osteogenic growth peptide enhances the proliferation of bone marrow mesenchymal stem cells from osteoprotegerin-deficient mice by CDK2/cyclin A. | Q42868212 | ||
| Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. | Q42918384 | ||
| Relationships between serum adiponectin, apelin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in post-menopausal Chinese women | Q43140284 | ||
| Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients | Q43409328 | ||
| Changes in pituitary adenylate cyclase-activating Peptide 27-like immunoreactive nervous structures in the porcine descending colon during selected pathological processes | Q43582500 | ||
| Amylin and bone metabolism in streptozotocin-induced diabetic rats | Q43599982 | ||
| Preptin analogues: chemical synthesis, secondary structure and biological studies | Q43703282 | ||
| Structure-activity relationship of ghrelin: pharmacological study of ghrelin peptides | Q43732032 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 579-640 | |
| P577 | publication date | 2016-03-28 | |
| P1433 | published in | Medicinal Research Reviews | Q2436033 |
| P1476 | title | Short Anabolic Peptides for Bone Growth | |
| P478 | volume | 36 |
Search more.